Combination of CA19-9 and Blood Free-Circulating Methylated &lt;b&gt;&lt;i&gt;RUNX3&lt;/i&gt;&lt;/b&gt; May Be Useful to Diagnose Stage I Pancreatic Cancer

Fujimoto, Yuko; Suehiro, Yutaka; Kaino, Seiji; Suenaga, Shigeyuki; Tsuyama, Takanori; Matsui, Hiroto; Higaki, Shingo; Fujii, Ikuei; Suzuki, Chieko; Hoshida, Tomomi; Matsumoto, Toshihiko; Takami, Taro; Nagano, Hiroaki; Sakaida, Isao; Yamasaki, Takahiro

doi:10.1159/000511940

Cited by 15 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of serum tumor markers in the diagnosis of pancreatic cancer is also the focus of clinical research. Fujimoto et al [ 12 ] combined the serum marker CA19-9 and methylated short stature-related transcription factor 3 (RUNX 3) in early pancreatic cancer screening and found that the sensitivity and the specificity of the two combined detection of pancreatic cancer were 85.5% and 93.5%, respectively, showing good diagnostic effect. Dong et al [ 13 ] analyzed the diagnostic value of CA19-9, CA 242, and serum peripherin (POSTN) for pancreatic cancer and finally found that CA19-9 and CA 242 combined with POSTN detection was a potential serum marker for the diagnosis of early pancreatic cancer.…”

Section: Introductionmentioning

confidence: 99%

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer

Qiao

He³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

The objective of this study was to analyze the value of artificial intelligence algorithm-based computerized tomography (CT) image combined with serum tumor markers for diagnoses of pancreatic cancer. In the study, 68 hospitalized patients with pancreatic cancer were selected as the experimental group, and 68 hospitalized patients with chronic pancreatitis were selected as the control group, all underwent CT imaging. An image segmentation algorithm on account of two-dimensional (2D)-three-dimensional (3D) convolution neural network (CNN) was proposed. It also introduced full convolutional network (FCN) and UNet network algorithm. The diagnostic performance of CT, serum carbohydrate antigen-50 (CA-50), serum carbohydrate antigen-199 (CA-199), serum carbohydrate antigen-242 (CA-242), combined detection of tumor markers, and CT-combined tumor marker testing (CT-STUM) for pancreatic cancer were compared and analyzed. The results showed that the average Dice coefficient of 2D-3D training was 84.27%, which was higher than that of 2D and 3D CNNs. During the test, the maximum and average Dice coefficient of the 2D-3D CNN algorithm was 90.75% and 84.32%, respectively, which were higher than the other two algorithms, and the differences were statistically significant ( P < 0.05 ). The penetration ratio of pancreatic duct in the experimental group was lower than that in the control group, the rest were higher than that in the control group, and the differences were statistically significant ( P < 0.05 ). CA-50, CA-199, and CA-242 in the experimental group were 141.72 U/mL, 1548.24 U/mL, and 83.65 U/mL, respectively, which were higher than those in the control group, and the differences were statistically significant ( P < 0.05 ). The sensitivity, specificity, positive predictive value, and authenticity of combined detection of serum tumor markers were higher than those of CA-50, CA-199, and CA-242, and the differences were statistically significant ( P < 0.05 ). The results showed that the proposed algorithm 2D-3D CNN had good stability and image segmentation performance. CT-STUM had high sensitivity and specificity in diagnoses of pancreatic cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer

Qiao

He³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Nevertheless, so far, the results from the validation study of the diagnostic gene panel developed by our group, which is based on hypermethylation of eight genes in combination with CA-19-9 shows a promising performance. This together with the other studies illustrating improved performance in combination with KRAS mutation [ 37 ] or CA-19-9 [ 36 ], indicate a panel of hypermethylated genes in combination with other diagnostic modalities might be needed to bolster the diagnostic power, which seems reasonable keeping in mind the molecular heterogenicity of PDAC.…”

Section: Cell-free Dna Methylation As Diagnostic Biomarkers For Pdacmentioning

confidence: 71%

“…RUNX3 methylation had a sensitivity of 50.9% for PDAC, with a 93.5% specificity using the total control group. By combining RUNX3 methylation and CA-19-9 the sensitivity increased substantial (85.5%) [ 36 ]. Furthermore, Keiko Shinjo and coworkers [ 37 ] examined methylation status of five genes ( ADAMTS1 , HOXA1 , PCDH10 , SEMA5A and SPSB4 in serum from patients with PDAC ( n = 47) and healthy controls ( n = 14).…”

Section: Cell-free Dna Methylation As Diagnostic Biomarkers For Pdacmentioning

confidence: 99%

Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update

Henriksen

Thorlacius-Ussing

2021

Epigenomes

View full text Add to dashboard Cite

Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed.

show abstract

“…The majority of patients are unresectable (75–80%) [ 20 , 21 , 22 , 23 ] and have a low 5-year overall survival rate [ 24 , 25 , 26 ]. CA19-9 is not recommended for screening early pancreatic cancer because of its limited sensitivity [ 27 , 28 , 29 ], especially in small tumors [ 30 ]. Hence, detection for early-stage PDAC and the evaluation of PDAC prognosis remain difficult problems.…”

Section: Discussionmentioning

confidence: 99%

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Xu¹,

Xiong²,

Yang³

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Nardilysin, (N-arginine dibasic convertase, NRDC) has been reported to play an important role in cancer progression, and is associated with tumor proliferation signals and inflammatory signals, such as tumor necrosis factor-a (TNF-a) and heparin-binding epidermal growth factor-like growth factor (HB-EGF), through the activation of disintegrin and metalloproteinase (ADAM) proteases. NRDC has recently been revealed to be involved in the tumorigenesis of various types of cancer, including intrahepatic cholangiocarcinoma, malignant cerebral infarction, esophageal squamous cell carcinoma, and gastric cancer. However, the expression profiles and biological relevance of NRDC in pancreatic ductal adenocarcinoma have rarely been reported. Methods: We analyzed the NRDC expression profile in pancreatic ductal adenocarcinoma by enzyme-linked immunosorbent assay (ELISA) and identified NRDC as a circulating biomarker in the serum of 112 pancreatic ductal adenocarcinoma patients. The diagnostic value of NRDC was analyzed by the area under the curve (AUC) and the receiver operating characteristic (ROC) test. Results: Our results demonstrated that the clinical prognosis significance of NRDC with the clinical characteristics in pancreatic ductal adenocarcinoma (PDAC). NRDC was notably decreased in PDAC patient serum compared with the control group (p < 0.001). Furthermore, the present study found that the NRDC expression level was correlated with T grade (p < 0.001), metastasis(p < 0.001), differentiation(p < 0.001), and TNM stage (p = 0.011). Further bioinformatics analysis revealed that NRDC correlated with proliferation and migration pathways; in particular, it mediated cell-matrix adhesion-dependent activation in pancreatic ductal adenocarcinoma. Conclusions: Serum NRDC may play a useful diagnostic biomarker to evaluate the aggressive clinical features in PAAD patients.

show abstract

Combination of CA19-9 and Blood Free-Circulating Methylated <b><i>RUNX3</i></b> May Be Useful to Diagnose Stage I Pancreatic Cancer

Cited by 15 publications

References 8 publications

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer

Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About